New hope for hard-to-treat cancers: triple therapy targets HER2-positive tumors
NCT ID NCT07506057
First seen Apr 02, 2026 · Last updated May 08, 2026 · Updated 8 times
Summary
This study tests a combination of two targeted drugs (trastuzumab and serplulimab) plus chemotherapy in 20 adults with advanced bile duct or bladder cancers that have stopped responding to standard treatments. The goal is to see if this triple therapy can shrink tumors and improve survival. Participants must have HER2-overexpressing tumors and be between 18 and 75 years old.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BILIARY TRACT CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital of China Medical University
RECRUITINGShenyang, Liaoning, 110001, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.